Oral laquinimod may reduce (at least in the initial phase of treatment) some of the more destructive pathological processes in RRMS patients.
2. 2nd International Symposium on Gait and Balance in Multiple Sclerosis: interventions for gait and balance in MS.
Department of Physical Medicine and Rehabilitation, Kennedy Krieger Institute, Johns Hopkins University School of Medicine , Baltimore, MD , USA .
3. Global N-acetylaspartate concentration in benign and non-benign multiple sclerosis patients of long disease duration.
4. Therapeutic Effects of Progesterone in Animal Models of Neurological Disorders.
5. Disease-association analysis of an inflammation-related feedback loop.
6. Electrodiagnostic evaluation of peripheral nervous system changes in patients with multiple sclerosis.
7. Prevalence of neurological disorders in Al Quseir, Egypt: methodological aspects.
8. Longitudinally extensive varicella-zoster virus myelitis in a multiple sclerosis patient.
9. Alpha-B-crystallin induces an immune-regulatory and antiviral microglial response in preactive multiple sclerosis lesions.
10. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) in humans with multiple sclerosis.
11. Muscle-specific kinase antibody positive myaesthenia gravis and multiple sclerosis co-presentation: A case report and literature review.
12. A patient's perspective of partnership in the treatment of multiple sclerosis: MS regimes-An orchestrated approach.
13. Global N-acetylaspartate concentration in benign and non-benign multiple sclerosis patients of long disease duration.
14. 2nd International Symposium on Gait and Balance in Multiple Sclerosis: interventions for gait and balance in MS.
15. Therapeutic Effects of Progesterone in Animal Models of Neurological Disorders.
16. Autoantibodies to Potassium Channel KIR4.1 in Multiple Sclerosis.
17. Pediatric Inflammatory Diseases. Part IV: Miscellaneous, Reye, PRES, Sarcoidosis.
18. Pediatric inflammatory diseases. Part I: multiple sclerosis.
19. Practical Aspects of Shortening Acquisition Time in Brain MR Susceptibility-Weighted Imaging.
20. β-Arrestins 1 and 2 are critical regulators of inflammation.
21. BIOGEN HAS 3 NEW MS TREATMENTS THEY ARE WORKING ON THAT ARE BEING PRESENTED AT THE WORLDWIDE MEETING OF NEUROLOGISTS: ECTRIMS
22. VIDEO GAME HELPS EASE SYMPTOMS OF MS! PLUS: MSers CAN ENROLL IN UNIVERSITY'S STUDY
READ 109 MORE STUDIES & STORIES BY CLICKING ON "Read More" BELOW:
23. "First Direct Measurement of Spinal Cord Myelin in Multiple Sclerosis"
24. MS News Channel Expert Neurologist: Brian R. Apatoff, MD, PhD: MULTIPLE SCLEROSIS AND PAIN
businesswire.com
26. Dancing With the Stars 2013’s Jack Osbourne Will “Persevere” After Wife Lisa Stelly’s Miscarriage
wetpaint.com
We suggest that our virtual reality program enables anticipatory PC and response mechanisms and might serve as a successful therapeutic alternative in situations in which conventional therapy is not readily available.
lep.co.uk
health.com
hellomagazine.com
31. Carboxypeptidase N-deficient mice present with polymorphic disease phenotypes on induction of experimental autoimmune encephalomyelitis.
Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.:
32. Structure-Kinetics Relationships - an overlooked parameter in hit-to-lead optimization: a case of cyclopentylamines as CCR2 antagonists.
33. Parental illness, attachment dimensions, and health beliefs: testing the cognitive-behavioural and interpersonal models of health anxiety.
huffingtonpost.com
prnewswire.com
sciencebusiness.net
dailyecho.co.uk
sciencedaily.com
cbc.ca
dailyrecord.com
41. Multiple sclerosis on the rise in region
dailystar.com
thestar.com
pharmafile.com
44. THE SCIENCE OF TRIPS & FALLS IS IMPORTANT READING FOR ALL MS'ers
45. Dad pleads for trial drug to slow progressive illnessDAD PLEADS FOR DRUG TRIAL TO SLOW HIS PRIGRESSIVE MS!
46. Adam Possner, MD: THE EPLEY MANEUVER....THE CLOSEST DOCTORS COME TO EXORCISM
47. SLIDESHOW: "17 Multiple Sclerosis Treatments"
48. Genzyme’s second MS drug in a month approved in Europe! With Lemtrada's EU nod, Sanofi preps for dual MS drug launches
Sanofi now has not one, but two big multiple sclerosis launches to get under way in Europe. Two weeks after nabbing EU approval for its new MS pill Aubagio, Sanofi got regulatory clearance for Lemtrada
49. Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth
prnewswire.com 50. Biogen: All Reasons For Bulls To Be Happy
seekingalpha.com
44. THE SCIENCE OF TRIPS & FALLS IS IMPORTANT READING FOR ALL MS'ers
45. Dad pleads for trial drug to slow progressive illnessDAD PLEADS FOR DRUG TRIAL TO SLOW HIS PRIGRESSIVE MS!
46. Adam Possner, MD: THE EPLEY MANEUVER....THE CLOSEST DOCTORS COME TO EXORCISM
47. SLIDESHOW: "17 Multiple Sclerosis Treatments"
48. Genzyme’s second MS drug in a month approved in Europe! With Lemtrada's EU nod, Sanofi preps for dual MS drug launches
Sanofi now has not one, but two big multiple sclerosis launches to get under way in Europe. Two weeks after nabbing EU approval for its new MS pill Aubagio, Sanofi got regulatory clearance for Lemtrada
49. Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth
prnewswire.com 50. Biogen: All Reasons For Bulls To Be Happy
seekingalpha.com
pmlive.com
53. NYT: Patients fear drug cost spikes under health law
nbcnews.com
pharmafile.com
nbcnews.com
54. Teva Copy to Boost Billionaire-Backed Drugmaker: Corporate India
bloomberg.com
56. Report exposes failings in care of new MS patients
scottishconservatives.com
57. European Commission Approves Genzyme’s Multiple Sclerosis Treatment Lemtrada™ (alemtuzumab)
thestreet.com
bloomberg.com
eveningtelegraph.co
scottishconservatives.com
57. European Commission Approves Genzyme’s Multiple Sclerosis Treatment Lemtrada™ (alemtuzumab)
thestreet.com
58. "Sometimes I find myself thinking pretty negative thoughts about my multiple sclerosis and I notice that my symptoms are worse"
59. "What is MS? Could You Have MS? 16 Multiple Sclerosis Symptoms (SLIDESHOW)"
60. 4 ways to manage double vision: Solutions to help manage this common symptom of MS
61. Terri Spats, Columnist & News Editor: MY COLUMN TODAY IS A MESSAGE TO THOSE WITH NO INVISIBLE ILLNESS
62. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort
Multiple Sclerosis Journal. 2013; 19(11): p. 1533-1538
63. Teriflunomide for the treatment of multiple sclerosis.Oh J, O'Connor PW. Semin Neurol. 2013 Jul;33(3):307-8. doi: 10.1055/s-0033-1354604. Epub 2013 Sep 21.
64. Endurance training is feasible in severely disabled patients with progressive multiple sclerosis. Skjerbæk A, Næsby M, Lützen K, Møller A, Jensen E, Lamers I, Stenager E, Dalgas U.
Mult Scler. 2013 Sep 20.
65. The relationship of cognitive impairment with neurological and psychiatric variables in multiple sclerosis patients.Karadayi H, Arisoy O, Altunrende B, Boztas HM, Sercan M.
Int J Psychiatry Clin Pract. 2013 Sep 19. [Epub ahead of print]
66. Altered likelihood of brain activation in attention and working memory networks in patients with multiple sclerosis: An ALE meta-analysis. Kollndorfer K, Krajnik J, Woitek R, Freiherr J, Prayer D, Schöpf V. Neurosci Biobehav Rev. 2013 Sep 18.
67. Circulating dendritic cells of multiple sclerosis patients are proinflammatory and their frequency is correlated with MS-associated genetic risk factors. Thewissen K, Nuyts AH, Deckx N, Wijmeersch BV, Nagels G, D'hooghe M, Willekens B, Cras P, Eijnde BO, Goossens H, Van Tendeloo VF, Stinissen P, Berneman ZN, Hellings N, Cools N. Mult Scler. 2013 Sep 20.
68. Multiple Sclerosis Outcome Assessments Consortium: Genesis and initial project plan. Rudick RA, Larocca N, Hudson LD; MSOAC. Mult Scler. 2013 Sep 20. [Epub ahead of print]
69. Outcomes after Microvascular Decompression for Patients with Trigeminal Neuralgia and Suspected Multiple Sclerosis.Ariai MS, Mallory GW, Pollock BE. World Neurosurg. 2013 Sep 19.
70. Risk factors related to cardiovascular diseases and the metabolic syndrome in multiple sclerosis - a systematic review. Wens I, Dalgas U, Stenager E, Eijnde BO.
Mult Scler. 2013 Sep 18. [Epub ahead of print]
71.Incidence and prevalence of multiple sclerosis in the UK 1990-2010: a descriptive study in the General Practice Research Database .Mackenzie IS, Morant SV, Bloomfield GA, Macdonald TM, O'Riordan J. J Neurol Neurosurg Psychiatry. 2013 Sep 19
72. Clinical significance of atrophy and white matter mean diffusivity within the thalamus of multiple sclerosis patients
Multiple Sclerosis Journal. 2013; 19(11): p. 1478-1484
73. What Is the JC Virus?
74. Royal recognition for Sussex Multiple Sclerosis Treatment Centre work
theargus.co
businesswire.com
southwalesargus.co
businesswire.com
sciencedaily.com
netdoctor.co
eurekalert.org
brightsurf.com
harrogateadvertiser.co
theolympian.com
bizjournals.com
85. "STING may take the bite out of autoimmune diseases"
86. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.
In Assessment of OraL Laquinimod in PrEventing ProGRession in Multiple SclerOsis (ALLEGRO), a phase III study in relapsing-remitting multiple sclerosis (RRMS), oral laquinimod slowed disability and brain atrophy progression, suggesting laquinimod may reduce tissue damage in MS. MRI techniques sensitive to the most destructive aspects of the disease were used to further investigate laquinimod's potential effects on inflammation and neurodegeneration. Oral laquinimod may reduce (at least in the initial phase of treatment) some of the more destructive pathological processes in RRMS patients.
87. A 10-year follow-up of a population-based study of people with multiple sclerosis in Stockholm, Sweden: Changes in disability and the value of different factors in predicting disability and mortality.
The aims of this study were to evaluate changes in disability over ten years in PwMS, and to explore the value of personal and disease-specific factors and depressive symptoms in predicting disability. A further aim was to explore the value of these factors as predictors of mortality.This study illustrates the importance of tailored interventions for PwMS and highlights the need for health-care professionals to consider the psychological aspects of the disease. Furthermore, our results indicate that the Expanded Disability Status Scale was a useful tool for predicting future disability.
88. The B1-cell subpopulation is diminished in patients with relapsing-remitting multiple sclerosis.
89. Oxidative modification of serum proteins in multiple sclerosis.
90. Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II).
Multiple Sclerosis Journal. 2013; 19(11): p. 1485-1492
Multiple Sclerosis Journal. 2013; 19(11): p. 1518-1525
Multiple Sclerosis Journal. 2013; 19(11): p. 1428-1436
J Child Neurol. published 23 September 2013, 10.1177/0883073813501873
96. "Why do some people experience aggressive worsening of their multiple sclerosis and others experience a mild course?"
silive.com
100. Girl Swims to to Reach Fundraising
montereyherald.com
102. Apitope Announces Positive Results from Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis
bionity.com
104. Swimming for a Cause: Scotts Valley youngster raises awareness, money for MS Association
insidebayarea.com
107. Manes & Motions: An Equine Assist For Special Needs
courant.com
108. Trekking Hadrian’s Wall for Multiple Sclerosis Society
115. Psychological and physical predictors of illness intrusiveness in patients with multiple sclerosis.
Ferkauf Graduate School of Psychology, Yeshiva University, United States; Multiple Sclerosis Center of Holy Name Medical Center, United States.: Snyder S, Foley FW, Farrell E, Beier M, Zemon V.
J Neurol Sci. 2013 Sep 15;332(1-2):41-4. doi: 10.1016/j.jns.2013.06.009. Epub 2013 Jul 10.
116. Reduced grey matter perfusion without volume loss in early relapsing-remitting multiple sclerosis.
New Zealand Brain Research Institute, , Christchurch, New Zealand.: Debernard L, Melzer TR, Van Stockum S, Graham C, Wheeler-Kingshott CA, Dalrymple-Alford JC, Miller DH, Mason DF. J Neurol Neurosurg Psychiatry. 2013 Sep 13.
Grey matter (GM) pathology in multiple sclerosis (MS) is associated with progressive long-term disability. Detection of GM abnormalities in early MS may therefore be valuable in understanding and predicting the long-term course. However, structural MRI measures such as volume loss have shown only modest abnormalities in early relapsing-remitting MS (RRMS). We therefore investigated for evidence of abnormality in GM perfusion, consistent with metabolic dysfunction, in early RRMS.
The decrease in GM perfusion in the absence of volume loss is consistent with neuronal metabolic dysfunction in early RRMS. Future studies in larger cohorts and longitudinal follow-up are needed to investigate the functional and prognostic significance of the early GM perfusion deficits observed.
117. Bipolar disorder and multiple sclerosis: A case series.
Department of Neurology, Razi Hospital, Mannouba, Tunis, Tunisia.: Sidhom Y, Djebara MB, Hizem Y, Abdelkefi I, Kacem I, Gargouri A, Gouider R.
Behav Neurol. 2013 Sep 12. [Epub ahead of print]
118. Delayed Recovery of Leg Fatigue Symptoms Following a Maximal Exercise Session in People With Multiple Sclerosis.
1Oxford Brookes University, Oxford, UK.: Dawes H, Collett J, Meaney A, Duda J, Sackley C, Wade D, Barker K, Izadi H.
Neurorehabil Neural Repair. 2013 Sep 11.
Symptoms of fatigue were investigated during and following a single exercise session.
Monitoring leg fatigue symptoms during and through recovery from physical activities may help guide participation in physical activities for PwMS, particularly in people managing high levels of fatigue.
119. Exacerbation of experimental autoimmune encephalomyelitis by passive transfer of IgG antibodies from a multiple sclerosis patient responsive to immunoadsorption.
Neuroimmunology and Neuromuscular Disorders Unit, Foundation IRCCS Neurological Institute C. Besta, Via Celoria 11, 20133 Milan, Italy. Electronic address: rpedotti@istituto-besta.it.: Pedotti R, Musio S, Scabeni S, Farina C, Poliani PL, Colombo E, Costanza M, Berzi A, Castellucci F, Ciusani E, Confalonieri P, Hemmer B, Mantegazza R, Antozzi C.
J Neuroimmunol. 2013 Sep 15;262(1-2):19-26.
120. Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis.
Cladribine causes sustained reduction in peripheral T and B cell populations while sparing other immune cells. We determined two populations of dendritic cells (DCs): namely CD1c(+)/CD19(-) (myeloid DCs) and CD303(+)/CD123(+) (plasmacytoid DCs), CD19(+) B lymphocytes, CD3(+) T lymphocytes and CD4(+) or CD8(+) subpopulations in patients with multiple sclerosis after cladribine therapy.
We noticed significant trend to increase the CD303(+) circulating the dendritic cells. This population produces large amounts of IFN-alfa. We found significant and rapid decrease in B cells and CD4(+) Th cells. Our results suggest two possible ways of beneficial cladribine influence on immune system in MS. Induction of IFN-alfa producing cells and their predominance over BDCA-1(+) DCs, which are associated with cytotoxic response. Additionally, cladribine could influence two populations of lymphocytes: B cells and Th lymphocytes responsible for induction of immune response against myelin antigens.
121. Intrathecal oligoclonal IgG synthesis in multiple sclerosis.
Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands; UCL Institute of Neurology, Neuroimmunology & CSF Laboratory, Queen Square, London, United Kingdom. Electronic address: a.petzold@vumc.nl.: J Neuroimmunol. 2013 Sep 15;262(1-2):1-10
Inez Wens, Ulrik Dalgas, Egon Stenager, and Bert O. Eijnde
Multiple Sclerosis Journal. published 18 September 2013
123. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort
124. Clinical significance of atrophy and white matter mean diffusivity within the thalamus of multiple sclerosis patients
Ralph HB Benedict, Hanneke E Hulst, Niels Bergsland, Menno M
Schoonheim, Michael G Dwyer, Bianca Weinstock-Guttman, Jeroen JG
Geurts, and Robert Zivadinov
Multiple Sclerosis Journal. 2013; 19(11): p. 1478-1484
125. Clinical characteristics and outcome of multiple sclerosis in Korea: does multiple sclerosis in
Korea really differ from that in the Caucasian populations?
131. CCSVI TERRIBLE NEWS! CANADIAN RESEARCHERS FAILED TO FIND ANY VEIN BLOCKAGES IN 99 OF 100 PATIENTS
132. Place of death, and its relation with underlying cause of death, in Parkinson’s disease, motor neurone disease, and multiple sclerosis: A population-based study Little is known about place of death
Wall Street Journal
UCSF News Services
137. Place
of death, and its relation with underlying cause of death, in
Parkinson’s disease, motor neurone disease, and multiple sclerosis: A
population-based study
Little is known about place of death in chronic neurological diseases. Mortality statistics are ideal for examining trends in place of death, but analyses are limited by coding rule changes. Underlying cause of death has a marked effect on place of death. The effects of coding rule changes are an essential consideration for all research using underlying cause of death to study place of death.
144. MS Walk connects people, raises fundsKilleen Daily Herald
145. A
telerehabilitation program by virtual reality-video games improves
balance and postural control in multiple sclerosis patients.
Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Faculty of Health Sciences, ReyJuanCarlosUniversity, Alcorcón, Madrid, Spain.: Gutiérrez RO, Galán Del Río F, Cano de la Cuerda R, Alguacil Diego IM, González RA, Page JC.
To demonstrate the potential improvements in balance and PC among patients with MS who complete a virtual reality telerehabilitation program that represents a feasible alternative to physical therapy for situations in which conventional treatment is not available.
We suggest that our virtual reality program enables anticipatory PC and response mechanisms and might serve as a successful therapeutic alternative in situations in which conventional therapy is not readily available.
146. Carboxypeptidase N-deficient mice present with polymorphic disease phenotypes on induction of experimental autoimmune encephalomyelitis.
Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.: Hu X, Wetsel RA, Ramos TN, Mueller-Ortiz SL, Schoeb TR, Barnum SR.
96. "Why do some people experience aggressive worsening of their multiple sclerosis and others experience a mild course?"
ctvnews.ca
kentucky.com
100. Girl Swims to to Reach Fundraising
montereyherald.com
cleveland.com
102. Apitope Announces Positive Results from Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis
bionity.com
businesswire.com
104. Swimming for a Cause: Scotts Valley youngster raises awareness, money for MS Association
insidebayarea.com
businesswire.com
theguardian.com
courant.com
108. Trekking Hadrian’s Wall for Multiple Sclerosis Society
horncastlenews.co
edmunds.com
prnewswire.com
silive.com
113. Assessing risks of multiple sclerosis therapies.
Service of Neurology, Department of Clinical Neurosciences, University Hospital of Lausanne, CHUV BH-10, 46 rue du Bugnon, 1011 Lausanne, Switzerland.: J Neurol Sci. 2013 Sep 15;332(1-2):59-65. doi: 10.1016/j.jns.2013.06.013.
Service of Neurology, Department of Clinical Neurosciences, University Hospital of Lausanne, CHUV BH-10, 46 rue du Bugnon, 1011 Lausanne, Switzerland.: J Neurol Sci. 2013 Sep 15;332(1-2):59-65. doi: 10.1016/j.jns.2013.06.013.
Clemens
Warnke, Anne K. Mausberg, Mark Stettner, Thomas Dehmel, Lina, Nekrich,
Gerd Meyer zu Horste, Hans-Peter Hartung, Anna Fogdell-Hahn, Ortwin
Adams, and Bernd C. KieseierNeurology. published 18 September 2013,
10.1212/WNL.0b013e3182a84101
115. Psychological and physical predictors of illness intrusiveness in patients with multiple sclerosis.
Ferkauf Graduate School of Psychology, Yeshiva University, United States; Multiple Sclerosis Center of Holy Name Medical Center, United States.: Snyder S, Foley FW, Farrell E, Beier M, Zemon V.
J Neurol Sci. 2013 Sep 15;332(1-2):41-4. doi: 10.1016/j.jns.2013.06.009. Epub 2013 Jul 10.
116. Reduced grey matter perfusion without volume loss in early relapsing-remitting multiple sclerosis.
New Zealand Brain Research Institute, , Christchurch, New Zealand.: Debernard L, Melzer TR, Van Stockum S, Graham C, Wheeler-Kingshott CA, Dalrymple-Alford JC, Miller DH, Mason DF. J Neurol Neurosurg Psychiatry. 2013 Sep 13.
Grey matter (GM) pathology in multiple sclerosis (MS) is associated with progressive long-term disability. Detection of GM abnormalities in early MS may therefore be valuable in understanding and predicting the long-term course. However, structural MRI measures such as volume loss have shown only modest abnormalities in early relapsing-remitting MS (RRMS). We therefore investigated for evidence of abnormality in GM perfusion, consistent with metabolic dysfunction, in early RRMS.
The decrease in GM perfusion in the absence of volume loss is consistent with neuronal metabolic dysfunction in early RRMS. Future studies in larger cohorts and longitudinal follow-up are needed to investigate the functional and prognostic significance of the early GM perfusion deficits observed.
117. Bipolar disorder and multiple sclerosis: A case series.
Department of Neurology, Razi Hospital, Mannouba, Tunis, Tunisia.: Sidhom Y, Djebara MB, Hizem Y, Abdelkefi I, Kacem I, Gargouri A, Gouider R.
Behav Neurol. 2013 Sep 12. [Epub ahead of print]
118. Delayed Recovery of Leg Fatigue Symptoms Following a Maximal Exercise Session in People With Multiple Sclerosis.
1Oxford Brookes University, Oxford, UK.: Dawes H, Collett J, Meaney A, Duda J, Sackley C, Wade D, Barker K, Izadi H.
Neurorehabil Neural Repair. 2013 Sep 11.
Symptoms of fatigue were investigated during and following a single exercise session.
Monitoring leg fatigue symptoms during and through recovery from physical activities may help guide participation in physical activities for PwMS, particularly in people managing high levels of fatigue.
119. Exacerbation of experimental autoimmune encephalomyelitis by passive transfer of IgG antibodies from a multiple sclerosis patient responsive to immunoadsorption.
Neuroimmunology and Neuromuscular Disorders Unit, Foundation IRCCS Neurological Institute C. Besta, Via Celoria 11, 20133 Milan, Italy. Electronic address: rpedotti@istituto-besta.it.: Pedotti R, Musio S, Scabeni S, Farina C, Poliani PL, Colombo E, Costanza M, Berzi A, Castellucci F, Ciusani E, Confalonieri P, Hemmer B, Mantegazza R, Antozzi C.
J Neuroimmunol. 2013 Sep 15;262(1-2):19-26.
120. Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis.
Cladribine causes sustained reduction in peripheral T and B cell populations while sparing other immune cells. We determined two populations of dendritic cells (DCs): namely CD1c(+)/CD19(-) (myeloid DCs) and CD303(+)/CD123(+) (plasmacytoid DCs), CD19(+) B lymphocytes, CD3(+) T lymphocytes and CD4(+) or CD8(+) subpopulations in patients with multiple sclerosis after cladribine therapy.
We noticed significant trend to increase the CD303(+) circulating the dendritic cells. This population produces large amounts of IFN-alfa. We found significant and rapid decrease in B cells and CD4(+) Th cells. Our results suggest two possible ways of beneficial cladribine influence on immune system in MS. Induction of IFN-alfa producing cells and their predominance over BDCA-1(+) DCs, which are associated with cytotoxic response. Additionally, cladribine could influence two populations of lymphocytes: B cells and Th lymphocytes responsible for induction of immune response against myelin antigens.
121. Intrathecal oligoclonal IgG synthesis in multiple sclerosis.
Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands; UCL Institute of Neurology, Neuroimmunology & CSF Laboratory, Queen Square, London, United Kingdom. Electronic address: a.petzold@vumc.nl.: J Neuroimmunol. 2013 Sep 15;262(1-2):1-10
Inez Wens, Ulrik Dalgas, Egon Stenager, and Bert O. Eijnde
Multiple Sclerosis Journal. published 18 September 2013
123. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort
Tomas Olsson, Anat Achiron, Lars Alfredsson, Thomas Berger, David
Brassat, Andrew Chan, Giancarlo Comi, Mefkure Eraksoy, Harald Hegen,
Jan Hillert, Poul Erik Hyldgaard Jensen, Lucia Moiola, Kjell-Morten
Myhr, Annette Oturai, Sven Schippling, Aksel Siva, Per Soelberg
Sorensen, Anne-Kathrin Trampe, Thomas Weber, James Potts, Tatiana
Plavina, Dominic Paes, Meena Subramanyam, Heinz Wiendl, Hussein Dib,
Deniz Uren, Bernhard Hemmer, and Dorothea Buck
Multiple Sclerosis Journal. 2013; 19(11): p. 1533-1538
Brassat, Andrew Chan, Giancarlo Comi, Mefkure Eraksoy, Harald Hegen,
Jan Hillert, Poul Erik Hyldgaard Jensen, Lucia Moiola, Kjell-Morten
Myhr, Annette Oturai, Sven Schippling, Aksel Siva, Per Soelberg
Sorensen, Anne-Kathrin Trampe, Thomas Weber, James Potts, Tatiana
Plavina, Dominic Paes, Meena Subramanyam, Heinz Wiendl, Hussein Dib,
Deniz Uren, Bernhard Hemmer, and Dorothea Buck
Multiple Sclerosis Journal. 2013; 19(11): p. 1533-1538
124. Clinical significance of atrophy and white matter mean diffusivity within the thalamus of multiple sclerosis patients
Ralph HB Benedict, Hanneke E Hulst, Niels Bergsland, Menno M
Schoonheim, Michael G Dwyer, Bianca Weinstock-Guttman, Jeroen JG
Geurts, and Robert Zivadinov
Multiple Sclerosis Journal. 2013; 19(11): p. 1478-1484
125. Clinical characteristics and outcome of multiple sclerosis in Korea: does multiple sclerosis in
Korea really differ from that in the Caucasian populations?
Su-Hyun Kim, So-Young Huh, Woojun Kim, Min Su Park, Suk-Won Ahn,
Joong-Yang Cho, Byung Jo Kim, and Ho Jin Kim
Multiple Sclerosis Journal. 2013; 19(11): p. 1493-1498
Joong-Yang Cho, Byung Jo Kim, and Ho Jin Kim
Multiple Sclerosis Journal. 2013; 19(11): p. 1493-1498
Joseph R Berger, Jennifer Pocoski, Ronald Preblick, and Susan Boklage
Multiple Sclerosis Journal. 2013; 19(11): p. 1526-1532
Multiple Sclerosis Journal. 2013; 19(11): p. 1526-1532
J Frau, D Cossu, G Coghe, L Lorefice, G Fenu, M Melis, D Paccagnini, C
Sardu, MR Murru, S Tranquilli, MG Marrosu, LA Sechi, and E Cocco
Multiple Sclerosis Journal. 2013; 19(11): p. 1437-1442
Sardu, MR Murru, S Tranquilli, MG Marrosu, LA Sechi, and E Cocco
Multiple Sclerosis Journal. 2013; 19(11): p. 1437-1442
Nete M Nielsen, Peter Bager, Egon Stenager, Bo V Pedersen, Nils
Koch-Henriksen, Henrik Hjalgrim, and Morten Frisch
Multiple Sclerosis Journal. 2013; 19(11): p. 1473-1477
Koch-Henriksen, Henrik Hjalgrim, and Morten Frisch
Multiple Sclerosis Journal. 2013; 19(11): p. 1473-1477
Violaine K Harris, Nicola Donelan, Qi Jiang Yan, Kristi Clark, Amir
Touray, Mustapha Rammal, and Saud A Sadiq
Multiple Sclerosis Journal. 2013; 19(11): p. 1462-1472
Touray, Mustapha Rammal, and Saud A Sadiq
Multiple Sclerosis Journal. 2013; 19(11): p. 1462-1472
132. Place of death, and its relation with underlying cause of death, in Parkinson’s disease, motor neurone disease, and multiple sclerosis: A population-based study Little is known about place of death
Wall Street Journal
Over
1,900 Biogen Idec (NASDAQ: BIIB) employees will trade in their lab
coats and computers today to participate in the company's third annual
"Care Deeply Volunteer Day."For this
day of service, Biogen Idec employees are given a paid day off to
volunteer at a service project in their community. This year, employees
are estimated to serve over 9,500 volunteer hours in more than 28
countries in the communities where the company operates.
134. UCSF Researcher First Winner of Prize for Innovative Work on Multiple SclerosisUCSF News Services
Telemanagement
Little is known about place of death in chronic neurological diseases. Mortality statistics are ideal for examining trends in place of death, but analyses are limited by coding rule changes. Underlying cause of death has a marked effect on place of death. The effects of coding rule changes are an essential consideration for all research using underlying cause of death to study place of death.
The
role of the adaptive immune system and more specifically T cells in the
pathogenesis of multiple sclerosis (MS) has been studied extensively.
Emerging evidence suggests that dendritic cells (DCs), which are innate
immune cells, also contribute to MS. DCs in MS are in a pro-inflammatory
state, have a migratory phenotype and are affected by genetic risk
factors, thereby contributing to pathogenic responses.
Kuwait
was considered as low to intermediate risk area for MS. Kuwait is
considered a high-risk area for MS. The significant increase in
prevalence and incidence rates may represent a true increase despite the
improvement in case ascertainment and case definition.
The New York Times
142. Proud MS team celebrates success at abseil challengeShoreham Herald
143. Meet The IESE MBA With A Passion For Health CareBusinessBecause
Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Faculty of Health Sciences, ReyJuanCarlosUniversity, Alcorcón, Madrid, Spain.: Gutiérrez RO, Galán Del Río F, Cano de la Cuerda R, Alguacil Diego IM, González RA, Page JC.
To demonstrate the potential improvements in balance and PC among patients with MS who complete a virtual reality telerehabilitation program that represents a feasible alternative to physical therapy for situations in which conventional treatment is not available.
We suggest that our virtual reality program enables anticipatory PC and response mechanisms and might serve as a successful therapeutic alternative in situations in which conventional therapy is not readily available.
146. Carboxypeptidase N-deficient mice present with polymorphic disease phenotypes on induction of experimental autoimmune encephalomyelitis.
Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.: Hu X, Wetsel RA, Ramos TN, Mueller-Ortiz SL, Schoeb TR, Barnum SR.
